Oncopeptides AB (OND) Q2 2026 Earnings Report
DE:OND Q2 2026 EPS Results
- Actual EPS
- -EUR 0.01
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -EUR 0.03
DE:OND Q2 2026 Revenue Results
- Actual Revenue
- EUR 2.84M
- Expected Revenue
- EUR 2.74M
- Beat/Miss
- Beat by +EUR 100.26K
- YoY Revenue Growth
- +62.03%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/27/2026
- Time
- Before Open
- Conference Call
- Thursday, August 27, 2026
Oncopeptides AB's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call was predominantly positive, supported by 62% quarterly revenue growth, 74% first-half growth, a 98% gross margin, improved EBIT loss, strengthened liquidity, European commercial progress, the EMA label-expansion submission, CEE partnership expansion, and clinical advancement in glioblastoma. These positives were moderated by the continuing operating loss, Spain's access and competitive challenges, no Q2 contribution from Greece, delays in Japan, the lack of current U.S. focus, and the still-broad timing for cash flow positivity.
Oncopeptides expects positive cash flow “during 2027,” with sales covering operating expenses, and expects full-year operating expenses “to be in the vicinity of what we had for 2025, i.e., around about SEK 300 million”; Q3 operating expenses are expected to be “slightly lower than Q2.” Following the Type II variation submission between May and July, the company expects the CHMP opinion “sometimes between September to November,” with an EC decision “+30 to 60 days after a potential positive opinion.” For the Salus partnership, “first sales should come sometime in 2027,” while sales in Slovenia can start once a price negotiation is concluded.
- Strong Revenue GrowthNet sales reached SEK 31.1 million in Q2 2026, representing a 62% increase compared with Q2 2025. First-half net sales reached SEK 56.5 million, up 74% year-over-year.
- High Gross Margin and Improved EBIT LossThe first-half gross margin was 98%. The EBIT loss improved to SEK 86.2 million from SEK 116.1 million in the prior-year period.
- Disciplined Cost ManagementFirst-half operating expenses decreased 2% year-over-year to SEK 146.9 million. Quarterly G&A costs decreased to SEK 16.7 million from SEK 18.6 million, while commercial investments were focused on European markets generating growth.
- Strengthened Liquidity PositionCash stood at SEK 158 million at the end of Q2. The rights issue completed in March contributed SEK 167 million after transaction costs, providing a firmer financial base. The company remains on track to reach positive cash flow during 2027.
- EMA Submission for Third-Line Multiple MyelomaOncopeptides submitted a Type II variation application to the EMA to expand Pepaxti's label from fourth-line to third-line multiple myeloma. The company expects a CHMP opinion between September and November, with an EC decision potentially following 30 to 60 days after a positive opinion.
- Potential Expansion of Addressable Patient PopulationThe proposed third-line indication would remove the triple-class refractory requirement and allow treatment after at least two prior lines, potentially doubling the target patient population in Europe. The company also stated that average treatment duration could potentially double based on phase III OCEAN data.
- Growing European Commercial AdoptionMore than 1,000 patients have been treated with Pepaxti across Europe since EMA approval. Germany delivered steady gains in monthly new patient starts and an expanding prescriber base, Italy continued to perform exceptionally well, and Spain achieved an all-time high monthly sales level in June.
- Germany Progressing Toward ProfitabilityGermany showed commercial momentum across university hospitals and office-based practices. With strict cost control and volume growth, the company said Germany is progressing toward country-level profitability for the full year.
- European Market Opportunity and ExclusivityThe current Pepaxti label addresses an estimated SEK 1.5 billion market potential across Europe, with market exclusivity protected until 2037.
- Central and Eastern Europe Partnership ExpansionOncopeptides signed a distribution agreement with Salus Group covering 11 countries in Central and Eastern Europe, representing an estimated SEK 150 million addressable market potential under the current label. The company secured a list price for Pepaxti in Slovenia, its first CEE expansion milestone, and identified Croatia and the Czech Republic as the next markets in the launch sequence.
- Glioblastoma Program Advanced Into Clinical StudyThe company received regulatory approval from Norwegian authorities, enrolled and dosed the first patient in its 10-patient glioblastoma window of opportunity study, completed the Safety Review Committee assessment, and initiated recruitment of additional patients.
- Pipeline and Scientific ProgressPreclinical data for the novel OPSP1 natural killer-cell engager was presented at the AACR annual meeting. Oncopeptides also presented five scientific abstracts and hosted a PDC symposium at the EHA Congress. Its pipeline includes OPD5 for glioblastoma, OPDC3 for enhanced selectivity in solid tumors, and OPSP1.
- Preclinical Differentiation of Glioblastoma CandidateThe company stated that its PDC demonstrated 100% blood-brain barrier penetration in preclinical testing and high glioblastoma cytotoxicity in in vitro and in vivo trials, appearing independent of the most common DNA-repair mutation.
- Continued Business Development ActivityOncopeptides remains engaged in active partnership discussions in Japan and other territories. The company is prioritizing European commercialization and a potential Japan partnership.
DE:OND Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 05, 2026 | 2026 (Q3) | ―- | -0.02 | ― | ― |
| Aug 27, 2026 | 2026 (Q2) | ―-0.01 | -0.03 | 49.12% (+0.01) | |
| May 13, 2026 | 2026 (Q1) | ―-0.01 | -0.02 | 52.94% (+0.01) | |
| Feb 19, 2026 | 2025 (Q4) | -0.02-0.02 | -0.03 | 31.01% (+0.01) | |
| Nov 05, 2025 | 2025 (Q3) | -0.24-0.02 | -0.02 | 1.16% (+0.00) | |
| Aug 21, 2025 | 2025 (Q2) | ―-0.03 | -0.04 | 33.72% (+0.01) | |
| May 15, 2025 | 2025 (Q1) | ―-0.02 | -0.06 | 61.77% (+0.04) | |
| Feb 27, 2025 | 2024 (Q4) | ―-0.03 | -0.05 | 39.47% (+0.02) | |
| Nov 07, 2024 | 2024 (Q3) | ―-0.02 | -0.03 | 9.15% (+0.00) | |
| Aug 14, 2024 | 2024 (Q2) | ―-0.04 | -0.04 | -8.65% (-0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
